Biocept (BIOC) Stock Heads For The Top On Commercial Launch

Biocept BIOC Stock News

After announcing news of a commercialization plan, Biocept Inc (NASDAQ: BIOC) is climbing in the market this morning. In a press release issued early this morning, the company said that it would be launching the Target Selector NGS Breast Panel.

As you could imagine, commercial launches lead to expectations of revenue growth. So, investors are naturally excited and the stock is running for the top. Here’s the deal:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BIOC Announces Commercial Launch

The news was issued about an hour ago in a press release. In the release, Biocept said that it would be launching its multi-gene liquid biopsy panel specifically developed for breast cancer. As with previously launched products, the Target Selector NGS Breast Panel runs on Thermo Fisher Scientific’s Ion Torrent.

The Ion Torrent is a next generation sequencing platform, or NGS platform. In the release, BIOC said that the Target Selector NGS Breast Panel will be marketed to physicians and researchers alike. The biopsy panel is designed for the detection and monitoring of actionable genomic biomarkers associated with breast cancer.

To make the Target Selector NBS Breast Panel possible, the company combined its laboratory and commercial infrastructure and its expertise in blood sample preservation and DNA/RNA isolation with Thermo Fisher’s industry leading NGS and informatics technology, known as Oncomine.

Ultimately, the company believes that the commercial launch will enrich the content that supports its collaboration with AI solutions provider, Prognos Health. In a statement, Michael Nall, President and CEO at BIOC, had the following to offer:

We are extremely pleased to launch our second multi-gene liquid biopsy panel, this one tailored to breast cancer, which expands our Target Selector family of offerings to physicians and researchers in both academic centers and the pharmaceutical industry.

This additional offering provides a unique liquid biopsy platform interrogating both CTCs and ctDNA in patients with breast cancer. We believe this dual approach enhances the identification of actionable genomic alterations to provide personalized treatment options

The multi-gene panel has undergone robust and extensive analytical and clinical validation to identify all main classes of genomic aberrations encountered in breast cancer, with an overall clinical accuracy of 99.8%, specificity of greater than 99% and sensitivity of greater than 90%.

Biocept remains the only commercial liquid biopsy company that can offer customers the flexibility to order either customized single biomarker assays or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired.

Why This News Is So Exciting

At the moment, breast cancer is the most commonly diagnosed form of cancer in women. Moreover, it is the second leading cause of cancer-related death among women. In the United States alone, more than a quarter million women are diagnosed with breast cancer every year, with more than 40,000 deaths from the disease.

In order to reduce mortality rates, physicians have been looking for ways to diagnose early and determine the status of actionable biomarkers to provide effective treatments for patients. That’s where the Target Selector NGS Breast Cancer Panel comes in.

The target selector helps doctors to understand which therapies are likely to have the best chance of success. Moreover, the Panel can be used to help breast cancer patients qualify for clinical trials.

Ultimately, there is likely to be a large demand for the company’s product as the panel has the potential to lead to better treatment outcomes for patients. So, the launch of the Target Selector NGS Breast Cancer Panel has the potential to drive significant revenue growth for Biocept and its investors.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Do You Think?

Where do you think BIOC stock is headed moving forward? Join the discussion in the comments below!

Stop Missing The News

Are you getting tired of missing the news? Join our mailing list below for FREE!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.